Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
抗CD22抗体药物偶联物Pinatuzumab Vedotin联合/不联合利妥昔单抗治疗复发/难治性B细胞非霍奇金淋巴瘤患者的I期研究
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-16-0772
Advani, Ranjana H; Lebovic, Daniel; Chen, Andy; Brunvand, Mark; Goy, Andre; Chang, Julie E; Hochberg, Ephraim; Yalamanchili, Sreeni; Kahn, Robert; Lu, Dan; Agarwal, Priya; Dere, Randall C; Hsieh, Hsin-Ju; Jones, Surai; Chu, Yu-Waye; Cheson, Bruce D